Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials.

Author: ChenHua, DengYing, DengYuxuan, FanJiapeng, HaoWensa, HeQi, LongZhiyong, YangKailin, ZengLiuting

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Iguiratimod (IGU) is an effective and safe intervention for Ankylosing Spondylitis (AS), decreasing BASDAI, BASFI, and VAS scores without increasing adverse events.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To explore the efficacy and safety of Iguratimod (IGU) intervention in the treatment of Ankylosing Spondylitis (AS). METHODS: We used computer to search literature databases, collected randomized controlled trials (RCTs) related to IGU treatment of AS, and searched the relevant literatur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020631/

データ提供：米国国立医学図書館（NLM）

Iguratimod: A Potential Oasis in the Desert of Ankylosing Spondylitis

Ankylosing spondylitis (AS), a chronic inflammatory disease, presents a challenging landscape for treatment. This study embarks on a journey through the world of Iguratimod (IGU), exploring its potential as a therapeutic agent for AS. Through a systematic review and meta-analysis of randomized controlled trials, the authors examined the efficacy and safety of IGU in managing AS. Their findings suggest that IGU can effectively reduce disease activity and symptoms, while also demonstrating a favorable safety profile.

A Glimpse of Hope in the Desert: IGU Shows Promise in Managing AS

The study found that IGU demonstrated a significant reduction in the BASDAI, BASFI, and VAS scores, indicating its potential to alleviate AS symptoms. These promising results are further supported by the finding that IGU did not significantly increase the risk of adverse events when combined with conventional therapy. This highlights the potential of IGU as a safe and effective treatment option for AS.

Navigating the Sands of Treatment: A Path Towards Improved Outcomes

The study encourages further research to explore the full potential of IGU in managing AS. This research provides a valuable starting point for patients and healthcare professionals seeking effective treatment options for this debilitating condition. The findings suggest that IGU may offer a pathway towards improved outcomes for individuals living with AS.

Dr.Camel's Conclusion

This study provides a glimmer of hope in the desert of AS treatment, highlighting the potential benefits of Iguratimod. While further research is needed to confirm its long-term efficacy and safety, the findings suggest that IGU could be a valuable tool in the fight against this challenging condition. The study encourages continued exploration of new therapeutic avenues to provide relief and improve the lives of individuals affected by AS.

Date :
  1. Date Completed 2023-03-21
  2. Date Revised 2023-03-27
Further Info :

Pubmed ID

36936924

DOI: Digital Object Identifier

PMC10020631

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.